Comparative Pharmacology
Head-to-head clinical analysis: NOVANTRONE versus PARAPLATIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NOVANTRONE versus PARAPLATIN.
NOVANTRONE vs PARAPLATIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mitoxantrone is a synthetic anthracenedione derivative that intercalates with DNA and inhibits topoisomerase II, leading to DNA strand breaks and inhibition of DNA and RNA synthesis. It also disrupts DNA repair and replication, and has immunosuppressive effects through inhibition of B cell, T cell, and macrophage function.
Carboplatin, a platinum-based alkylating agent, forms interstrand and intrastrand DNA cross-links by binding to DNA guanine bases, inhibiting DNA replication and transcription, leading to cell cycle arrest and apoptosis.
12 mg/m2 IV over 5-15 minutes once daily on days 1-3 of a 28-day cycle, or as a single dose of 12-14 mg/m2 IV every 21 days. For acute nonlymphocytic leukemia, 12 mg/m2 IV daily for 3 days with cytarabine.
360 mg/m2 IV every 3 weeks or area under the curve (AUC) 4-6 mg/mL/min IV every 3-4 weeks using Calvert formula.
None Documented
None Documented
Terminal elimination half-life: 23-215 hours (mean ~37 hours). The long half-life reflects extensive tissue distribution and slow elimination, allowing weekly dosing.
Terminal elimination half-life: 2.6-5.1 hours (initial phase), 22-52 hours (terminal phase) for total platinum; 1.3-2.1 hours for ultrafilterable platinum. Clinically, the terminal half-life reflects slow release of protein-bound platinum.
Primarily hepatic (biliary/fecal) elimination: ~25% as unchanged drug and metabolites in feces over 5 days; renal excretion accounts for ~11% (6-11%) as unchanged drug. Less than 10% excreted unchanged in urine.
Renal excretion: ~70-90% of platinum is excreted in urine within 24 hours, primarily as unchanged drug. Fecal excretion: <6%. Biliary excretion: minimal.
Category C
Category C
Antineoplastic Agent
Antineoplastic Agent